FAM19A4/miR124-2 Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years.

Frederique J Vink,Chris J L M Meijer,Albertus T Hesselink,Arno N Floore,Birgit I Lissenberg-Witte,Jesper H Bonde,Helle Pedersen,Kate Cuschieri,Ramya Bhatia,Mario Poljak,Anja Oštrbenk Valenčak,Peter Hillemanns,Wim G V Quint,Marta Del Pino,Gemma G Kenter,Renske D M Steenbergen,Daniëlle A M Heideman,Maaike C G Bleeker

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America（2023）

引用 2|浏览38

暂无评分

摘要

Compared with HPV16/18 genotyping, the FAM19A4/miR124-2 methylation test detects nonproductive, transforming CIN2/3 lesions with high specificity in women aged <30 years, providing clinicians supportive information about the need for treatment of CIN2/3 in young HPV-positive women.

查看译文

关键词

HPV E4,cervical cancer,cervical intraepithelial neoplasia,host cell DNA methylation,human papillomavirus,p16ink4a/Ki-67 immunoscore

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要